C-Reactive Protein Testing Market - Global Forecast 2025-2030

The C-Reactive Protein Testing Market size was estimated at USD 1.69 billion in 2024 and expected to reach USD 1.91 billion in 2025, at a CAGR 12.45% to reach USD 3.42 billion by 2030.

C-Reactive Protein (CRP) testing has emerged as a cornerstone diagnostic tool for detecting and monitoring inflammation across a spectrum of clinical conditions. A CRP test quantitatively measures the level of C-reactive protein produced by the liver in response to inflammatory stimuli, making it indispensable for identifying acute infections, autoimmune disorders, and gastrointestinal and pulmonary diseases. High-sensitivity CRP (hs-CRP) assays have further enhanced clinical utility by enabling early detection of cardiovascular risk, supported by studies demonstrating predictive value for events decades ahead. These assays report results in milligrams per deciliter, guiding healthcare providers in preventive strategies and treatment adjustments.

The landscape of CRP testing has undergone transformative innovation with the advent of point-of-care platforms that deliver rapid, on-site results without the need for central laboratories. These portable analyzers have revolutionized emergency and remote healthcare settings by reducing turnaround times to mere minutes, thereby enabling clinicians to make timely therapeutic decisions. Concurrently, automated laboratory systems now process high volumes of samples with unrivaled precision, integrating seamlessly into digital health ecosystems and electronic health records to streamline data management and optimize patient monitoring.

In April 2025, the United States implemented a universal 10% import tariff on most goods, encompassing active pharmaceutical ingredients, medical devices, and diagnostic instruments such as CRP analyzers and reagents. China-specific duties have escalated dramatically, with cumulative rates reaching 145% on lab-related imports, while Canada and Mexico face select levies on non-USMCA goods and energy products. These measures have driven up procurement costs for reagents and kits, pressured supply chains, and prompted device manufacturers to reevaluate sourcing and pricing strategies. Notably, Roche has engaged directly with U.S. policymakers to seek tariff relief, highlighting the risk of inflated costs and disrupted diagnostic access.

A nuanced understanding of market segmentation reveals how diversified product portfolios and targeted delivery models are reshaping competitive dynamics. In the instruments segment, laboratories and point-of-care settings demand analyzers that balance throughput with mobility, while reagent developers compete on assay sensitivity and kit stability for both conventional and high-sensitivity CRP platforms. Consulting services and data management software providers are increasingly bundling analytics solutions with hardware to enhance value propositions. Technological segmentation underscores a shift toward immunoturbidimetric and nephelometric methods, with latex-enhanced formats driving higher specificity in automated workflows. End users ranging from academic research institutes to tiered clinic networks and hospital-based laboratories exhibit distinct requirements, urging manufacturers to customize service support and training programs. Application-focused insights show that cardiovascular disease screening commands the largest share, yet infection and inflammatory disorder diagnostics are the fastest-growing niches, fueled by rising autoimmune disorder prevalence. Finally, test types from quantitative automated to semi-quantitative lateral-flow formats and sample matrices spanning plasma, serum, and whole blood illustrate the market’s push for versatility and decentralized testing.

Regional markets for CRP testing are influenced by healthcare infrastructure maturity, regulatory frameworks, and disease burden patterns. In the Americas, robust reimbursement mechanisms and widespread hospital laboratory networks support early adoption of high-sensitivity assays, cementing North America’s leadership in diagnostic innovation. Within Europe, Middle East & Africa, stringent clinical guidelines and preventive cardiology initiatives have spurred uptake of hs-CRP testing for long-term risk assessment in both public and private healthcare systems, with notable advocacy by cardiology societies for standardized screening protocols. Asia-Pacific markets are experiencing the fastest expansion due to surging prevalence of chronic inflammatory diseases, increased government funding for healthcare modernization, and strategic partnerships that facilitate technology transfer and local manufacturing.

Market leadership in CRP testing is defined by the strategic agility of companies to navigate regulatory shifts, tariff landscapes, and technological disruptions. Roche Diagnostics has responded to U.S. tariff challenges by pledging significant domestic investments to mitigate cost pressures and secure supply chains. Abbott Laboratories has countered pricing headwinds with a $500 million infusion into new U.S. manufacturing and research facilities, ensuring continuity of its diagnostic reagent supply. Siemens Healthineers, renowned for its high-end imaging and laboratory solutions, is integrating artificial intelligence-driven analytics into hs-CRP platforms to deliver predictive insights and enhance clinical decision support. Thermo Fisher Scientific and Danaher (Beckman Coulter) continue to expand assay menus and pursue subscription-based consumable models, reinforcing their dominance in centralized laboratory environments. Across the competitive landscape, incumbents and emerging entrants alike are prioritizing interoperability, data connectivity, and bundled service offerings to differentiate in an increasingly commoditized market.

Industry leaders should accelerate investments in point-of-care and decentralized testing platforms that align with healthcare providers’ demand for rapid, actionable diagnostics. By forging partnerships with digital health and data analytics firms, companies can offer integrated solutions that elevate patient monitoring and treatment efficacy. To mitigate tariff-induced cost volatility, manufacturers ought to diversify supplier networks and explore localized production strategies alongside lobbying efforts for diagnostic exemptions. Expanding clinical education programs and establishing regional centers of excellence will foster adoption and demonstrate real-world impact. Developing flexible, subscription-based business models for analyzers and consumables can reduce capital expenditure barriers for laboratories and clinics, stimulating broader market penetration. Finally, continuous innovation in high-sensitivity assays and multiplexed inflammatory panels will reinforce differentiation in a landscape where clinical precision and operational efficiency are paramount.

This report synthesizes insights from a robust research methodology encompassing both primary and secondary sources. Primary research involved in-depth interviews with senior executives, laboratory directors, and key opinion leaders across geographies to capture firsthand perspectives on market dynamics, unmet needs, and investment priorities. Secondary research leveraged peer-reviewed journals, industry white papers, government publications, and credible news outlets to validate market trends, tariff policies, and technological advancements. Data triangulation and rigorous quality checks ensured consistency across multiple data points, while expert panels reviewed preliminary findings to refine projections and strategic implications. The comprehensive approach supports actionable recommendations and provides decision-makers with reliable, up-to-date intelligence on the C-Reactive Protein testing landscape.

In summary, C-Reactive Protein testing is poised at the intersection of inflammatory disease management and precision diagnostics, underpinned by technological innovations and evolving clinical guidelines. While high-sensitivity assays and point-of-care platforms drive growth and market differentiation, external factors such as U.S. tariff regimes and supply chain dynamics demand strategic agility. Segmentation analysis reveals nuanced opportunities across instrument formats, assay technologies, end-user settings, and clinical applications. Regional market disparities underscore the importance of tailored strategies that account for reimbursement policies, guideline adoption, and local manufacturing capabilities. Leading companies are differentiating through investment in digital integration, localized production, and novel business models. By adopting the recommended strategic imperatives, industry participants can capitalize on the growing demand for inflammation diagnostics and secure a competitive advantage in the global C-Reactive Protein testing market.

For tailored insights and an in-depth exploration of trends shaping the future of C-Reactive Protein testing, reach out to Ketan Rohom, Associate Director of Sales & Marketing at our firm. He will guide you through the comprehensive report’s methodologies, segmentation analyses, and strategic recommendations to ensure you gain a competitive edge. Connect with Ketan to discuss customized research solutions, licensing options, and enterprise packages designed to address your organization’s specific requirements. Elevate your decision-making with the definitive market intelligence on C-Reactive Protein testing-contact Ketan Rohom today to secure your copy and drive transformative growth.